openFDA
Cure8 regulatory brief
Why This Matters
Hydrocortisone injection is an FDA‑labelled corticosteroid option for short‑term control of severe flares or life‑threatening situations when oral therapy isn't feasible; the label explicitly names regional enteritis (Crohn's) and ulcerative colitis among gastrointestinal indications.
Patients and clinicians may encounter this product during hospitalization for acute IBD exacerbations or other inflammatory emergencies.
Who Should Pay Attention
Clinicians who treat hospitalized or acutely ill IBD patients, patients with severe IBD flares requiring parenteral therapy, inpatient nurses and pharmacists, and caregivers of people who may need emergency intravenous corticosteroids.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is a U.S. FDA (DailyMed) label update for hydrocortisone sodium succinate for injection.
The label lists indications, dosing, administration guidance, and cautions for intravenous or intramuscular use, including use "to tide the patient over a critical period" in regional enteritis (Crohn's disease) and ulcerative colitis, as well as many other inflammatory, allergic, endocrine, and rheumatologic indications.
Dosage sections emphasize emergency intravenous administration, usual dosing ranges, and the recommendation to switch to longer-acting or oral corticosteroids after the initial emergency period. The label update is a regulatory record (drug-label) and does not present new clinical trial results.
It is best read as a reference for approved indications, dosing options, and administration cautions for hydrocortisone sodium succinate injection.
Keep In Mind
This DailyMed entry is the official FDA‑label text describing approved indications and dosing; it is a regulatory document, not a clinical study. Labels summarize recommended use and safety considerations but do not replace clinician judgment.
For individualized treatment decisions (choice of steroid, dose adjustments, switching to longer‑acting agents, or monitoring), consult treating clinicians.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorApotex Corp.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 28, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SOLU-MEDROL FDA label update (2026-07-23)
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Dexamethasone FDA label update (2026-07-17)
The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...
METHYLPREDNISOLONE SODIUM SUCCINATE FDA label update (2026-07-24)
This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...